Key facts
- This page summarizes Jonathan Alspaugh's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2021, 17:21.
Jonathan Alspaugh - 16 Aug 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SYRE
- Reported as of
- 16 Aug 2021
- Net transaction value
- +$262,660
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2021, 17:21:54 UTC
- Prior SEC filing
- 08 Jul 2021
- Next SEC filing
- 13 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Weber, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Alspaugh filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 18 Aug 2021.
Change
- Previous filing in this sequence was filed on 08 Jul 2021.
- Current net transaction value: +$262,660.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGLE
transaction
Common Stock
Purchase
- Transaction value
- $62,275
- Shares
- +9,780
- Change %
- Price
- $6.37*
- Shares after
- 9,780
- Date
- 16 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
AGLE
transaction
Common Stock
Purchase
- Transaction value
- $151,985
- Shares
- +23,392
- Change %
- +239%
- Price
- $6.50*
- Shares after
- 33,172
- Date
- 17 Aug 2021
- Ownership
- Direct
- Footnotes
- F2
AGLE
transaction
Common Stock
Purchase
- Transaction value
- $48,400
- Shares
- +7,200
- Change %
- +22%
- Price
- $6.72*
- Shares after
- 40,372
- Date
- 18 Aug 2021
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
Footnote F2
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive.
Footnote F3
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive.